X0508 4 2026-01-02 0001070081 PTC THERAPEUTICS, INC. PTCT 0001578852 Boulding Mark Elliott C/O PTC THERAPEUTICS, INC. 500 WARREN CORPORATE CENTER DRIVE WARREN NJ 07059 false true false false EXEC. VP AND CLO 1 Common Stock 2026-01-02 4 A 0 17000 0 A 120901 D Common Stock 2026-01-05 4 M 0 2266 39.42 A 123167 D Common Stock 2026-01-05 4 S 0 1123 74.92 D 122044 D Common Stock 2026-01-05 4 S 0 1035 76.10 D 121009 D Common Stock 2026-01-05 4 S 0 108 76.79 D 120901 D Stock Option (Right to Buy) 76.74 2026-01-02 4 A 0 42500 0 A 2036-01-01 Common Stock 42500 42500 D Stock Option (Right to Buy) 39.42 2026-01-05 4 M 0 2266 0 D 2033-01-04 Common Stock 2266 9063 D Restricted stock units granted on January 2, 2026 that vest in four equal installments over four years, commencing on January 2, 2027. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $74.55 to $75.27 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.58 to $76.42 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.75 to $76.81 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This option was granted on January 2, 2026, and vests over four years, with 25% of the shares underlying the option vesting on January 2, 2027, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2027. This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. /s/ Avraham S. Adler, Attorney-in-Fact 2026-01-06